Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
National Hospital Organization Kyushu Cancer Center · Kanagawa Cardiovascular and Respiratory Center · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
749
total citations
- FWCI
- 57.44
- Percentile
- 100%
- References
- 27
Citations per year
Authors
19- TSTakashi Seto
National Hospital Organization Kyushu Cancer Center
- TKTerufumi Kato
Kanagawa Cardiovascular and Respiratory Center
- MNMakoto Nishio
The Cancer Institute Hospital, Japanese Foundation For Cancer Research
- KGKōichi Goto
National Cancer Center Hospital East
- SAShinji Atagi
NHO Kinki Chuo Chest Medical Center
Topics & keywords
Topics
Keywords
- Erlotinib
- Medicine
- Bevacizumab
- Internal medicine
- Oncology
- Tolerability
- Lung cancer
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.